New Opportunities for Value Creation: How Biotechs Can Succeed in an Increasingly Competitive Market

The game has changed in biotech. Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many. Companies who earlier would have been sellers, may now be progressing development through registrational studies — or all the way through to market. Stated another way, biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma — accordingly, players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. With these new challenges come multifold new opportunities for value creation.

Syneos Health and Treehill Partners are at the center of this landscape, devising concerted product, corporate and business development strategies with customers to navigate the evolving market.

In this webinar, the featured speakers will discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.

The speakers also look to address some pressing questions such as:

• How far to go as a biotech (and in what circumstances)
• Value focused clinical development
• Strategic capital allocation
• How patients may benefit in the long run from the evolution and increasing sophistication of the biotech ecosystem

Register now to learn about new opportunities for biotechs for value creation.

Speakers

Lee Taurman, Global Head of Syneos One, Syneos Health

Lee Taurman is an experienced life sciences industry executive and management consultant. He is the Global Head of Syneos One, leading the growth of integrated and innovative offering that spans clinical, medical affairs and commercialization.

Lee specializes in working with clients to develop innovative solutions as they evolve to meet the needs of a changing healthcare and business landscape. This includes developing innovative services and solutions, reorganizing and restructuring to better manage costs and creating new approaches to strategic planning and execution that unlock shareholder value.

Lee previously led Grant Thornton’s advisory practice for Life Sciences. His work with clients focused on creating internal and external innovation platforms to deliver business value. He also developed strategies and execution models to harness the power of the “gig economy” and help manage an increasingly externalized non-employee workforce.

Read more...

He previously acted as Executive Vice President of Corporate Strategic Development for Mylan. In this role he served as a member of the Executive Leadership Team and was responsible globally for corporate strategy, the company’s business transformation efforts, business analytics and health innovation solutions.

Lee spent over a decade as a management consultant and executive at PricewaterhouseCoopers and IBM Global Business Services where he led the Life Sciences Strategy and Transformation practice.

Read Less...

Message Presenter

Keith Ruark, SVP Strategic Business Development, Syneos Health

Keith Ruark is a senior life sciences professional bringing experience in leading tailored asset development and integrated clinical/commercial partnerships.

Keith is an executive leader of the Syneos Health business development organization responsible for structuring strategic partnerships and tailored solutions that leverage global infrastructure and capabilities to maximize value and outcomes for an asset/drug portfolio.

His experience at Syneos Health includes the past four years as one of the principal and founding team members involved in the development of the company’s unique Syneos One business unit as a partnership vehicle from planning through tailored delivery, underpinning a number of unique integrated product development relationships with clients.

Read more...

Much of Keith’s 25 years’ experience in the healthcare industry has included positions at the intersection of drug development and commercialization, including experience within R&D, marketing, management consulting and business/corporate development functions.

Within Keith’s career in life sciences, he has had material involvement in the structuring, negotiation and management of over $500m in product-based and company investments and is part of the working team to set up pharmaceutical product infrastructure.

Read Less...

Message Presenter

Ali Pashazadeh, Founder, Treehill Partners

Ali Pashazadeh is a senior biotech strategy advisor and negotiator with a multi-disciplinary strategic mindset. He is ultimately accountable for delivery of client value on all Treehill Partners’ engagements. He is involved as a senior sponsor in a majority of projects and available to clients for strategic and tactical advice.

He puts to work a synthesis of strategic expertise, cross-functional insight and deep hands-on medical understanding when advising clients on their core strategies.

He completed M&A and financing assignments worth above $40 billion, including various landmark transactions in the pharma and biotech sector.

Message Presenter